Gestational Diabetes Mellitus: Efficacy of Non-Pharmacological Interventions for Management and Prevention

Naika Dubois1, Isabelle Giroux2,3

  • 1Interdisciplinary School of Health Sciences, Faculty of Health Sciences, University of Ottawa, Ottawa, ON K1N6N5, Canada.

PubMed

Background: Gestational diabetes mellitus (GDM) is a type of diabetes diagnosed during pregnancy and its prevalence is on the rise around the world. GDM increases the risk of serious adverse health outcomes for the mother and child. Multiple types of non-pharmacological interventions have been developed for the management and prevention of GDM; however, there is a lack of clarity regarding their effectiveness. Objective: To summarize the evidence on the efficacy of non-pharmacological interventions in the management and prevention of GDM. Methods: For this integrative review, a comprehensive literature search was conducted in the databases MEDLINE, CINAHL, Embase, Scopus, and Web of Science. The methodology followed the integrative approach outlined by Whittemore and Knafl's, and study quality was evaluated using the Mixed Methods Assessment Tool. Results: A total of 44 relevant studies were included. Key themes identified for GDM management were (1) nutrition therapy and physical activity, (2) social and psychological support, (3) digital tools, and (4) barriers and facilitators. For GDM prevention, themes were categorized into individual-level approaches, (5) lifestyle and supplements, and population-level approaches: (6) environmental factors, and (7) health in all policies. Conclusions: The growing prevalence of GDM is a major public health concern that requires the implementation of effective multi-level evidence-based strategies. Environmental, socioeconomic, and racial determinants of health have substantial impacts on GDM, highlighting the need to address the root causes of the illness. Further research is needed to support effective preventive and management measures beyond standard pharmacological treatment, so that evidence-based solutions can be applied to enhance and safeguard the health of current and future generations.

Related Concept Videos

Diabetes Mellitus: Type 2 and Gestational01:22

Diabetes Mellitus: Type 2 and Gestational

Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
4.3K
Diabetes: Management and Pharmacotherapy01:15

Diabetes: Management and Pharmacotherapy

The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
868
Pathophysiology of Diabetes01:20

Pathophysiology of Diabetes

Diabetes mellitus is a chronic metabolic disorder characterized by hyperglycemia. The four categories of diabetes are type 1 diabetes, type 2 diabetes, other specific types of diabetes, and gestational diabetes.
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility,...
3.2K
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
585
Hypoglycemia and Glucagon01:15

Hypoglycemia and Glucagon

Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
835
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
594